APTO-253
Modify Date: 2025-08-25 11:04:24
APTO-253 structure
|
Common Name | APTO-253 | ||
|---|---|---|---|---|
| CAS Number | 1422826-80-9 | Molecular Weight | 367.387 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C22H14FN5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of APTO-253APTO-253 is a small molecule inducer of KLF4, stabilizes G-quadruplex DNA and reduces MYC mRNA expression and protein levels; APTO-253 is converted intracellularly from a monomer to a ferrous complex [Fe(253)3]; selectively induces CDKN1A (p21), promotes G0-G1 cell-cycle arrest, and triggers apoptosis in acute myeloid leukemia (AML) cells without producing myelosuppression in various animal species and humans, induces DNA Damage in AML cells. Blood Cancer Phase 1 Clinical |
| Name | APTO-253 |
|---|
| Description | APTO-253 is a small molecule inducer of KLF4, stabilizes G-quadruplex DNA and reduces MYC mRNA expression and protein levels; APTO-253 is converted intracellularly from a monomer to a ferrous complex [Fe(253)3]; selectively induces CDKN1A (p21), promotes G0-G1 cell-cycle arrest, and triggers apoptosis in acute myeloid leukemia (AML) cells without producing myelosuppression in various animal species and humans, induces DNA Damage in AML cells. Blood Cancer Phase 1 Clinical |
|---|---|
| References | References 1. Tsai CY, et al. Mol Cancer Ther. 2018 Apr 6. doi: 10.1158/1535-7163.MCT-17-0834. 2. Cercek A, et al. Invest New Drugs. 2015 Oct;33(5):1086-92. 3. Wang B, et al. Biochem Biophys Res Commun. 2017 Mar 11;484(3):486-492. 4. Local A, et al. Mol Cancer Ther. 2018 Apr 6. doi: 10.1158/1535-7163.MCT-17-1209. View Related Products by Target c-Myc Blood Cancer |
| Molecular Formula | C22H14FN5 |
|---|---|
| Molecular Weight | 367.387 |